Carboplatin plus paclitaxel versus carboplatin plus stealth liposomal doxorubicin in patients with advanced ovarian cancer (AOC): Final results of the MITO-2 randomized multicenter trial

被引：0
|
作者：
Pignata, S.
Scambia, G.
Savarese, A.
Sorio, R.
Breda, E.
Ferrandina, G.
Gebbia, V.
Musso, P.
Gallo, C.
Perrone, F.
机构：
[1] Ist Nazl Tumori, Naples, Italy
[2] Univ Cattolica Sacro Cuore, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] CRO, Aviano, Italy
[5] Osped Fatebenefratelli, Rome, Italy
[6] Univ Palermo, Casa Cura La Maddalena, Palermo, Italy
[7] Osped Oncol, M Ascoli ARNAS, Palermo, Italy
[8] Univ Naples 2, Naples, Italy
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Pegylated liposomal doxorubicin and carboplatin versus paclitaxel and carboplatin as first-line treatment for Chinese patients with ovarian cancer: A multi-center, randomized, open-label trial
    Shen, Yuanming
    Kong, Beihua
    Xia, Bairong
    Wang, Fei
    Yin, Rutie
    Li, Qingshui
    Yue, Ying
    Kang, Shan
    He, Liping
    Wang, Ke
    Meng, Yuanguang
    Wang, Shixuan
    Qu, Pengpeng
    Huang, Xianghua
    Guo, Ruixia
    Yan, Ping
    Pan, Mei
    Lou, Ge
    Cheng, Wenjun
    Xie, Xing
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [32] Paclitaxel plus carboplatin versus paclitaxel plus alternating carboplatin and cisplatin for initial treatment of advanced ovarian cancer: long-term efficacy results: a Hellenic Cooperative Oncology Group (HeCOG) study
    Aravantinos, G
    Fountzilas, G
    Kosmidis, P
    Dimopoulos, MA
    Stathopoulos, GP
    Pavlidis, N
    Bafaloukos, D
    Papadimitriou, C
    Karpathios, S
    Georgoulias, V
    Papakostas, P
    Kalofonos, HP
    Grimani, E
    Skarlos, DV
    ANNALS OF ONCOLOGY, 2005, 16 (07) : 1116 - 1122
  • [33] Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR)
    Sehouli, J.
    Chekerov, R.
    Reinthaller, A.
    Richter, R.
    Gonzalez-Martin, A.
    Harter, P.
    Woopen, H.
    Petru, E.
    Hanker, L. C.
    Keil, E.
    Wimberger, P.
    Klare, P.
    Kurzeder, C.
    Hilpert, F.
    Belau, A. K.
    Zeimet, A.
    Bover-Barcelo, I.
    Canzler, U.
    Mahner, S.
    Meier, W.
    ANNALS OF ONCOLOGY, 2016, 27 (12) : 2236 - 2241
  • [34] Comparison of Neoadjuvant Chemotherapy Efficiency in Advanced Ovarian Cancer Patients Treated With Paclitaxel Plus Carboplatin and Intraperitoneal Bevacizumab vs. Paclitaxel With Carboplatin
    Tao, Yin
    Tang, Xue-Ting
    Li, Xing
    Wu, An-Shan
    Zhou, Hou-Shen
    Zhou, Cheng-fang
    FRONTIERS IN MEDICINE, 2022, 9
  • [35] Paclitaxel (175 mg/m2) plus carboplatin (6 AUC) versus paclitaxel (225 mg/m2)plus carboplatin (6 AUG) in advanced non-small-cell lung cancer (NSCLC):: A multicenter randomized trial
    Kosmidis, P
    Mylonakis, N
    Skarlos, D
    Samantas, E
    Dimopoulos, M
    Papadimitriou, C
    Kalophonos, C
    Pavlidis, N
    Nikolaidis, C
    Papaconstantinou, C
    Fountzilas, G
    ANNALS OF ONCOLOGY, 2000, 11 (07) : 799 - 805
  • [36] Pegylated Liposomal Doxorubicin and Carboplatin Compared With Paclitaxel and Carboplatin for Patients With Platinum-Sensitive Ovarian Cancer in Late Relapse
    Pujade-Lauraine, Eric
    Wagner, Uwe
    Aavall-Lundqvist, Elisabeth
    Gebski, Val
    Heywood, Mark
    Vasey, Paul A.
    Volgger, Birgit
    Vergote, Ignace
    Pignata, Sandro
    Ferrero, Annamaria
    Sehouli, Jalid
    Lortholary, Alain
    Kristensen, Gunnar
    Jackisch, Christian
    Joly, Florence
    Brown, Chris
    Le Fur, Nathalie
    du Bois, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3323 - 3329
  • [37] AGE-RELATED EFFICACY AND SAFETY OF FIRST LINE BEVACIZUMAB PLUS CARBOPLATIN-PACLITAXEL IN ADVANCED OVARIAN CANCER (AOC).
    Ricci, C.
    Salutari, V.
    Petrillo, M.
    Amadio, G.
    Paris, I.
    Fagotti, A.
    De Vincenzo, R.
    Distefano, M.
    Palluzzi, E.
    Giovannoni, S.
    Ferrandina, M. G.
    Scambia, G.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2016, 26 : 688 - 688
  • [38] A randomised phase II study of carboplatin plus liposomal doxorubicin (CLD) vs carboplatin plus paclitaxel (CP) in potentially platinum sensitive ovarian cancer patients. A Hellenic Cooperative Oncology Group study
    Linardou, H.
    Bafaloukos, D.
    Bamias, A.
    Xanthakis, I.
    Kalofonos, H. P.
    Aravantinos, G.
    Kosmidis, P.
    Briasoulis, E.
    Klouvas, G.
    Dmopoulos, A. M.
    EJC SUPPLEMENTS, 2007, 5 (04): : 312 - 312
  • [39] Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in very platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III GCIG trial.
    Mahner, S.
    Meier, W.
    Du Bois, A.
    Brown, C.
    Lorusso, D.
    Ferrero, A.
    Cretin, J.
    Havsteen, H.
    Bessette, P.
    Angleitner-Boubenizek, L.
    Vergote, I. B.
    Vasey, P. A.
    Gebski, V.
    Slama, B.
    Herrstedt, J.
    Kaizer, L.
    Georgoulopoulos, A.
    Reed, N.
    Wagner, U.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [40] EXPLORATORY RESULTS OF A PHASE IB TRIAL OF PACLITAXEL AND CARBOPLATIN plus GALUNISERTIB IN PATIENTS WITH UTERINE AND OVARIAN CARCINOSARCOMA
    Washington, Christina
    Gunderson-Jackson, Camille
    Walker, Joan
    Mannel, Robert
    Holman, Laura
    Richardson, Debra
    Neelakantan, Deepika
    Cohoon, Andrew
    Bhattacharya, Resham
    Ding, Kai
    Dwivedi, Shailendra
    Gatalica, Zoran
    Qian, Liangyue
    Moxley, Katherine
    Landrum, Lisa
    Rowland, Michelle
    Moore, Kathleen
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2022, 32 : A192 - A193
12345